We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-4.06%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$128M
AUM Growth
-$13.8M
Cap. Flow
-$1.69M
Cap. Flow %
-1.33%
Top 10 Hldgs %
76.57%
Holding
60
New
3
Increased
5
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$638K
2
BLUE
bluebird bio
BLUE
+$578K
3
ELUT icon
Elutia
ELUT
+$536K
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$358K
5
PGNY icon
Progyny
PGNY
+$297K

Top Sells

Rank Stock Value
1
ALBO
Albireo Pharma Inc
ALBO
+$2.53M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$1.5M
3
ATEC icon
Alphatec Holdings
ATEC
+$141K
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$117K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$102K

Sector Composition

Rank Sector Weight
1 Healthcare 96.37%
2 Energy 3.59%
3 Consumer Staples 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$50.5M 39.54%
728,585
+800
+0.1% +$56.4K
BDSX icon
2
Biodesix
BDSX
$209M
$9.37M 7.34%
251,982
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$8.53M 6.68%
84,240
– –
PRTA icon
4
Prothena Corp
PRTA
$453M
$6.22M 4.87%
128,395
+1,200
+0.9% +$63.4K
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$5.46M 4.28%
61,306
– –
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.38B
$4.69M 3.68%
249,400
– –
HROW icon
7
Harrow
HROW
$1.74B
$3.81M 2.98%
180,000
– –
UTHR icon
8
United Therapeutics
UTHR
$22.7B
$3.36M 2.63%
15,000
– –
OVV icon
9
Ovintiv
OVV
$16.2B
$3.04M 2.38%
84,200
– –
MASI
10
DELISTED
Masimo
MASI
$2.82M 2.21%
15,280
– –
PHR icon
11
Phreesia
PHR
$662M
$2.67M 2.09%
82,700
– –
ELUT icon
12
Elutia
ELUT
$42M
$2.5M 1.96%
1,655,184
+140,000
+9% +$536K
FHTX icon
13
Foghorn Therapeutics
FHTX
$305M
$1.64M 1.29%
264,843
– –
AXDX
14
DELISTED
Accelerate Diagnostics
AXDX
$1.58M 1.23%
225,239
– –
ALKS icon
15
Alkermes
ALKS
$8.79B
$1.41M 1.1%
50,000
– –
INBX
16
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.33M 1.04%
70,448
– –
ATEC icon
17
Alphatec Holdings
ATEC
$1.31B
$1.25M 0.98%
80,000
-10,000
-11% -$141K
KPTI icon
18
Karyopharm Therapeutics
KPTI
$216M
$1.13M 0.89%
19,422
– –
CORT icon
19
Corcept Therapeutics
CORT
$9.72B
$1.08M 0.85%
50,000
– –
DCGO icon
20
DocGo
DCGO
$64.3M
$952K 0.75%
110,000
– –
VTYX
21
DELISTED
Ventyx Biosciences
VTYX
$884K 0.69%
26,400
+4,400
+20% +$171K
CYTK icon
22
Cytokinetics
CYTK
$10.9B
$880K 0.69%
25,000
– –
PTGX icon
23
Protagonist Therapeutics
PTGX
$9.06B
$874K 0.68%
38,000
– –
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$792K 0.62%
12,000
– –
PXD
25
DELISTED
Pioneer Natural Resource Co.
PXD
$776K 0.61%
3,800
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Birchview Capital held 60 positions worth $128M, down 9.8% from $142M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Birchview Capital's Q1 2023 filing shows 3 new, 5 increased, 1 reduced and 5 closed positions. Its largest new stake was Travere Therapeutics: 30,000 shares worth $675K. The largest sale was Albireo Pharma Inc, an estimated $2.53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2023 buy was Travere Therapeutics: 30,000 shares worth $675K.
  • Birchview Capital added most to bluebird bio in Q1 2023, an estimated $578K increase.
  • Birchview Capital's biggest Q1 2023 reduction was Alphatec Holdings, cutting an estimated $141K.
  • Birchview Capital fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $2.53M.
  • Birchview Capital's ten largest holdings make up 77% of its $128M portfolio in Q1 2023.
  • Birchview Capital opened 3 new positions and closed 5 in Q1 2023.
  • Birchview Capital's portfolio value fell 9.8% quarter-over-quarter to $128M.

Based on Birchview Capital's 13F filing for Q1 2023, filed 12 May 2023.